Arrhythmogenic Right Ventricular Cardiomyopathy or Dilated Cardiomyopathy associated with Partial Hypopituitarism

Hao Thai Phan

Department of Internal Medicine. Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.

Abstract

Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC), also known as arrhythmogenic right ventricular dysplasia, is a heritable heart-muscle disorder that predominantly affects the right ventricle. Progressive loss of right ventricular myocardium and its replacement by fibrofatty tissue is the pathological hallmark of the disease. Case Report: A 25-year-old female presented with dyspnea from last one year. Her symptoms included fatigue, weakness, inability to lose weight, puffiness, and constipation. Echocardiogram and cardiac MRI were consistent with diagnostic criteria of ARVC formulated in 2010 by the revisited Task Force, with two major or one major and two minor criteria or four minor criteria. Conclusion: Cardiac magnetic resonance (MRI) is considered the best imaging modality in evaluating the RV in ARVC.

Keywords: Arrhythmogenic Right Ventricular Dysplasia, Dyspnea, Echocardiography, Heart Ventricles, Magnetic Resonance Imaging.

Case Report

A 25-year-old female presented with dyspnea for last one year. She was diagnosed as systemic lupus erythematosus by a hospital in our city one year ago. Her symptoms included fatigue, weakness, inability to lose weight (or weight gain), puffiness, and constipation. She did not attain menarche. Physical examination showed periorbital puffiness, brittle hair and eyebrow loss. She had a past history of brain tumor 17 years ago at the age of 8 years. Her treatment for brain tumor was surgery, chemotherapy and radiation therapy. Subsequently she stopped taking medicines and treatment plan as per her family decision.

Chest X-ray demonstrated increased heart-thorax index [Fig.1]. ECG showed right axis deviation, and incomplete right bundle block [Fig.2]. This prompted further endocrine workup that revealed the presence of hypoadrenalism, hypogonadism and growth hormone deficiency.
Partial hypopituitarism from previous intracranial surgery was diagnosed [Table 1]. Transthoracic echocardiogram showed normal left ventricular systolic function with ejection fraction of 53%, normal size and wall thickness of the left ventricle, slightly dilated left atrium, enlargement of the right ventricle 50 mm and right ventricular outflow tract 47 mm with reduced contractile function, tricuspid annular plane systolic excursion (TAPSE) 11 mm, apical, aneurysm-akinesia, endocardial ventricular hypertrabeculation especially at apex; mild mitral regurgitation and severe tricuspid regurgitation; and medium pericardial effusion without right ventricular depression [Fig.3]. Cardiac MRI showed normal volume and function of the left ventricle (EF 55%), right ventricle with 114 ml/m² indexed end-diastolic volume, reduced right ventricular function (EF 29.6%), areas of dyskinesia of the free wall at the mid and apex; late gadolinium enhancement of the free wall right ventricle at the mid and apex; hypertrabeculation of septal wall at the apex; medium pericardial effusion, no cardiac tamponade [Fig.4]. ARVC was diagnosed on the basis of revised 2010 task force criteria for ARVC as mentioned in Table 2 [7].

Differential diagnosis is dilated cardiomyopathy associated with partial hypopituitarism. If hypopituitarism promptly responds to multiple hormone replacement therapy, definite diagnosis would be dilated cardiomyopathy associated with partial hypopituitarism.
Discussion

ARVC causes 11-22% of sudden cardiac death in the young athletes patient population, resulting in approximately 22% of cases in athletes in northern Italy [4] and about 17% of sudden cardiac death in young people in the United States [5]. The pathologic hallmark of disease is myocardial atrophy (myocyte loss), fibrofatty replacement, fibrosis and thinning of the wall with chamber dilation and aneurysm formation [6]. The genetics of the disease seems to support the hypothesis that it may be caused by desmosomal dysfunction (mutation of plakophilin-2, desmoglein-2, desmocollin-2, desmoplakin genes), that lead to impaired mechanical and electrical coupling between individual cells, leading to myocyte uncoupling, especially under conditions that increase myocardial strain, for example during physical effort.

Diagnosis of ARVC relies on a scoring system, formulated in 2010 by the revisited Task Force, with two major or one major and two minor criteria or four minor criteria based on the demonstration of a combination of defects in right ventricular morphology and function, characteristic depolarization/repolarization electrocardiogram abnormalities (negative T waves and/or “epsilon” waves in right precordial leads), characteristic tissue pathology, typical arrhythmias, family history, and the results of genetic testing [7]. Cardiac magnetic resonance (MRI) is considered the best imaging modality in evaluating the RV in ARVC and provides tissue characterization and identification of intra-myocardial fat and fibrosis in addition to assessment of ventricular structure and function.

Conclusion

Cardiac magnetic resonance (MRI) is considered the best imaging modality in evaluating the RV in ARVC and provides tissue characterization and identification of intramyocardial fat and fibrosis in addition to assessment of ventricular structure and function.

Contributors: HTP wrote the manuscript, did literature search, involved in patient management, and approved the final version of this article. He will act as guarantor of the study.

Funding: None; Competing interests: None stated.

References

1. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129-133.
2. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurencette JL, Malergue C, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384-398.

Table 1: Laboratory findings.

|                         | Results | Normal Value |
|-------------------------|---------|--------------|
| Insulin like growth factor 1 | <25     | 100-350 ng/mL |
| Adrenocorticotropic hormone | 2.62   | 7.2-63.3 pg/mL |
| Anti microsomal antibody (TPOAb) | 15.75 | <34 U/L |
| Follicle stimulating hormone | 0.616  | 3-153 mUI/mL |
| Leutinizing hormone       | <0.1    | 2-64 mUI/mL  |
| Prolactin                 | 17.8    | 6-30 ng/mL   |
| Estradiol (E2)            | <5      | 12.5-650 pg/mL |
| Progesterone              | <0.03   | 4-25 ng/mL   |
| Human growth hormone      | <0.05   | <8 ng/mL     |

Table 2: 2D Echo Criteria of ARVC as per revised 2010 task force criteria.

| Major                  |                      |
|------------------------|----------------------|
| Regional RV akinesia,  |                      |
| dyskinesia, or aneurysm|                      |
| AND one of the         |                      |
| following measured at  |                      |
| end diastole:          |                      |
| - PLAX RVOT ≥ 32 mm (PLAX/BSA ≥ 19 mm/m²), or | |
| - PSAX RVOT ≥ 36 mm (PSAX/BSA ≥ 21 mm/m²), or | |
| - Fractional area change ≤ 33% | |

| Minor                  |                      |
|------------------------|----------------------|
| Regional RV akinesia,  |                      |
| dyskinesia or dyssynchronous RV | |
| contraction AND one of |                      |
| the following measured |                      |
| at end diastole:       |                      |
| - PLAX RVOT ≥ 29 to <32 mm (PLAX/BSA ≥ 16 to <19 mm/m²), or | |
| - PSAX RVOT ≥ 32 to <36 mm (PSAX/BSA ≥ 18 to <21 mm/m²), or | |
| - Fractional area change > 33% ≤ 40% | |
3. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113:1807-1816.

4. Corrado D, Fontaine G, Marcus FI, McKenna WJ, Nava A, Thiene G, et al. Arrhythmogenic right ventricular dysplasia cardiomyopathy: need for an international registry. Study Group on arrhythmogenic right ventricular dysplasia cardiomyopathy of the working groups on myocardial and pericardial disease and arrhythmias of the European Society of cardiology and of the scientific council on cardiomyopathies of the world heart federation. Circulation. 2000;101:E101-E106.

5. Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005;112:3823-3832.

6. Thiene G, Basso C, Danieli G, Rampazzo A, Corrado D, Nava A. Arrhythmogenic right ventricular cardiomyopathy a still underrecognized clinic entity. Trends Cardiovasc Med. 1997;7:84-90.

7. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-1541.